Nulibry™ (fosdenopterin) – New orphan drug approval
February 26, 2021 - The FDA announced the approval of BridgeBio Pharma’s Nulibry (fosdenopterin), to reduce the risk of mortality in patients with molybdenum cofactor deficiency (MoCD) Type A.
Download PDF
